Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Efavaleukin Alfa in Moderately to Severely Active Ulcerative Colitis
2023-506004-93-00Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 26
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Efavaleukin alfa with Placebo (2 arms). Primary endpoint: Clinical remission at week 12. Started May 2024; status: completed.
02
Drugs
efavaleukin alfa
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-506004-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506004-93-00.